OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Good news - thanks Tabasco! This is in addition to the positive results they are getting with another drug in development, TroVax, so should (hopefully!) be a good long-term hold.

Early trading rather confusing - up 13% immediately following 7 x buys of 30,000 (probably all the same trade !!) and then nothing but sells and back to scratch in minutes. It will be interesting to see how the day unfolds.

Interesting to note that today I came across TroVax having been identified by a major pharmaceutical company as a potential threat to their established drug, for a certain type of cancer therapy.

what ho ms T!

| For Immediate Release | 5 AUGUST 2009 |
+---------------------------------------------------+--------------------------+


OXFORD BIOMEDICA: NOTICE OF 2009 INTERIM RESULTS


RESULTS DATE: 27 AUGUST 2009
Oxford, UK - 5 August 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy
company, today announces that it will be releasing its interim results for the
six months ended 30 June 2009 on Thursday, 27 August 2009.
Analyst meeting: An analyst briefing will be held at 10:00am on Thursday, 27
August 2009 at the offices of Buchanan Communications, 45 Moorfields, London
EC2Y 9AE.
Web cast: Simultaneously to the analyst briefing at 10:00am, there will be a
live audio web cast of the presentation. To connect to the web cast facility,
please go to the Company's website: http://www.oxfordbiomedica.co.uk/
approximately 10 minutes (09:50am) before the start of the briefing. This will
also be available for replay shortly after the presentation.
-Ends-

Whilst it is nice to read of Listed Companies prepared to release web-casts, it is a great shame there isn't a common-format with some "trial" presentation so we punters can align our PC's.
- - - - I have tried past Web-casts on OXB's site but had no success......

The instruction to connect 10mins before the presentation leaves little time to check your settings. (that is, even if I had nothing better to do, ahem).

Hangon: you may need to download some software. I've not had a problem with webcasts from OXB and others, and I just use a 'normal' laptop. There's usually a link on the site to whatever it is you need (e.g. Media Player or whatever).

Re webcasts: These are run by Buchanan Communications (comms company for OXB and many other minnows). The link below is from their website (http://www.buchanan.uk.com/output/). You need to input your details and then proceed - it usually works.

Registration page for webcast

Good luck!

RNS Number : 0372X
Oxford Biomedica PLC
07 August 2009








For Immediate Release


7 AUGUST 2009




OXFORD BIOMEDICA TO PRESENT AT CANACCORD ADAMS GLOBAL GROWTH CONFERENCE



Oxford, UK - 7 August 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy company, is pleased to announce that John Dawson, its Chief Executive Officer, will present a company update on Tuesday, 11 August 2009 at 9.30am ET (2.30pm BST) at the Canaccord Adams 29th Annual Global Growth Conference being held in Boston, MA.

-Ends-

A sudden flurry of BUYS and the crossing of the all important 11.5 if you're into graph analysis - I'm hoping this is the start of another major rally and should see 20p soon. Maybe good news to come in the 6mth update 27AUG

RNS Number : 6531X
Oxford Biomedica PLC
19 August 2009










For Immediate Release


19 AUGUST 2009


OXFORD BIOMEDICA ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT ON TROVAX PHASE III TRIST STUDY FOR PRESENTATION AT ECCO 15-34th ESMO CONGRESS

Oxford, UK - 19 August 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that its late-breaking abstract on the Phase III TRIST study of TroVax, its therapeutic cancer vaccine, in renal cancer has been selected for oral presentation at the joint 15th Congress of the European CanCer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO) in Berlin, Germany. Detailed results from the most recent interim analysis of the TRIST study will be presented during a session on 'Genitourinary malignancies - Renal and Other' on 22 September 2009 from 9:00am to 11:15am CET.

The abstract is entitled 'TRIST: A randomised, double blind, placebo controlled Phase III study of MVA-5T4 in metastatic renal cancer patients'. It has been assigned an abstract number of 17LBA in the programme and abstract book, which is expected to be available at www.ecco-org.eu. A special European Journal of Cancer Supplement will also be printed and will include the TRIST abstract amongst other late-breaking and 'best' abstracts from the Congress. These abstracts will receive the highest visibility possible for an abstract presented at this conference.

The Phase III TRIST study is evaluating TroVax plus standard of care against placebo plus standard of care. The trial enrolled 733 patients with advanced or metastatic renal cancer. Despite not achieving its primary endpoint, follow-up analyses of the TRIST study have yielded valuable insights into the efficacy of TroVax, demonstrating further evidence of clinical activity and significant survival advantages to TroVax in subsets of patients.

John Dawson, Oxford BioMedica's Chief Executive Officer, said: 'We are delighted that our late-breaking abstract on the TRIST study has been accepted for presentation at the ECCO 15-34th ESMO Congress. This provides an opportunity for us to present our data at one of the world's most well-attended and high-profile cancer conferences. There are some positive findings from our recent analyses of the TRIST study and we look forward to presenting these to the oncology community.'



-Ends-

Reiteration of Oxford Biomedica by Panmure Gordon to hold...I intend to!.

Good morning allI dont think the sp will do much on until we are told of Partnership deals for ProsavinHi-8Meland Trovaxthere are supposed to be a number of interested parties in Trovaxrumoured eightsolid news on this front needed to push the sp towards 20pgiven the current 12p+ doubled since Aprilhopefully news any minute. fingers crossed.

Interims out today:

OXB - Interim results

Rodman & Renshaw Conference (Oxford Biomedica)


TIDMOXB

RNS Number : 4981Y
Oxford Biomedica PLC
04 September 2009

?


+---------------------------------------------------+--------------------------+
| For immediate release | 4 SEPTEMBER 2009 |
+---------------------------------------------------+--------------------------+






OXFORD BIOMEDICA TO PRESENT AT RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE


Oxford, UK - 4 September 2009: Oxford BioMedica (LSE: OXB), a leading gene
therapy company, announced today that John Dawson, its Chief Executive Officer,
will present at the Rodman & Renshaw Annual Global Investment Conference to be
held on 9-11 September at the New York Palace Hotel in New York City. The
presentation is scheduled on Thursday, 10 September at 2.50pm ET (7.50pm BST).
-Ends-

Forty trades or so in the last half hour mostly buyingsmall but unusual for oxb???

it's got to break out soon...

RNS Number : 4181Z
Oxford Biomedica PLC
22 September 2009








For Immediate Release


22 SEPTEMBER 2009




OXFORD BIOMEDICA PRESENTS INTERIM RESULTS FROM PHASE III TRIST STUDY OF TROVAX IN RENAL CANCER



Oxford, UK - 22 September 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy company, today announces interim results from its Phase III TRIST study of TroVax, a therapeutic cancer vaccine, in renal cancer. Although TroVax did not show a significant survival advantage compared to placebo in the total population (median survival of 20.1 months vs. 19.2 months; n = 732; p = 0.55), the survival advantage was significant in one of the predefined subsets, namely in patients with a good prognostic profile receiving interleukin-2 (IL-2) as standard of care (n = 100; p = 0.046). Additional exploratory analyses have confirmed that the anti-5T4 immune response induced by TroVax is associated with enhanced survival (p = 0.002)1, and have also identified haematological factors that were predictive of a more favourable immune response and greater survival benefit from TroVax.

The Principal UK Investigator for the study, Professor Robert Hawkins of the Christie Hospital in Manchester, is presenting the TRIST results today at the joint 15th Congress of the European CanCer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology

(ESMO) in Berlin, Germany. The abstract (#17LBA) can be viewed at http://www.ecco-org.eu.


The interim analysis of the TRIST study reflects validated survival data censored to 13 March 2009. Of 732 evaluable patients, the total reported deaths were 165 in the TroVax arm and 166 in the placebo arm. For the majority of patients (>80%), the reported cause of death was disease progression. At the cut-off date, 401 patients (55%) were still on study with a median follow-up of 13 months. The interim analysis showed that:


*

In the Intent to Treat population, estimated median survival for TroVax was 20.1 months versus 19.2 months for placebo (n = 732; p = 0.55).
*

In patients with a good prognostic profile receiving IL-2, TroVax reduced the risk of death by 46% compared to placebo (n = 100; hazard ratio (HR) = 0.54; p = 0.046). Median survival for the TroVax subset had not been reached versus 19.6 months for placebo.
*

The magnitude of the 5T4 antibody response to TroVax correlated with improved survival (p = 0.02)1, reinforcing similar observations in prior Phase II trials.
*

The anti-vector (MVA) response showed no analogous association, suggesting that survival is unrelated to patients' general health status and immune competence. This further supports the assumption that the 5T4 antibody response is clinically active.
*

Baseline platelet levels were predictive of a more favourable immune response to TroVax. The immune response was significantly more favourable in patients with 'normal' baseline platelets (n = 232) compared to 'abnormal' (n = 57), (p = 0.002)2.
*

Lower baseline platelet and monocyte levels and higher baseline haemoglobin levels were associated with increased survival benefit for TroVax versus placebo.
*

In patients with 'normal' baseline levels of these three haematological parameters, TroVax showed a promising trend in overall survival and an indicative 27% reduction in the risk of death versus placebo (n = 368; HR =0.73). The hazard ratio attained in this subset was consistent with the targeted primary endpoint for the TRIST study.
*

TroVax was well tolerated alongside standard of care and did not alter the serious or non-serious adverse event profile compared to placebo. The most common (>20%) treatment-related adverse events were pyrexia, fatigue, weight loss and nausea.

TRIST (TroVax Renal Immunotherapy Survival Trial) is a randomised Phase III study comparing TroVax to placebo, when added to first line standard of care. The trial enrolled 733 patients with advanced or metastatic renal cancer that were classified as having a good or intermediate prognosis. Patients were randomised to one of three standards of care: IL-2, interferon-alpha or sunitinib. As previously reported, vaccinations were discontinued on 11 July 2008 based on the recommendation of the study's independent Data Safety Monitoring Board, which concluded that the study would not meet its predefined primary endpoint of an improvement in overall survival.


Professor Hawkins commented on the TRIST interim analysis: 'The results presented today demonstrate that TroVax has a good safety profile and potentially improves patient survival in certain subsets of renal cancer. Importantly, the magnitude of the 5T4 immune response appears to correlate with clinical activity. The identification of baseline factors that may be predictive of a more favourable response to TroVax provides an excellent opportunity to optimise the design of future studies. Although I am disappointed that the trial did not meet its primary endpoint, I believe that TroVax is still of potential benefit to patients with cancer and I hope further studies will be initiated with more refined target populations.'


John Dawson, Oxford BioMedica's Chief Executive Officer, added: 'We are encouraged by the positive findings from our detailed analyses of the TRIST data. With these results, we aim to progress discussions with prospective partners and the oncology community in order to initiate further trials of TroVax as soon as possible. We are grateful to the clinical investigators and patients that participated in the TRIST study, whose contribution has significantly advanced our understanding of TroVax and its potential as a safe and effective therapeutic cancer vaccine.'

1. Log of ratio of 5T4 antibody titre at week 10 to baseline

2. Ratio of MVA to 5T4 antibody fold increase at week 10


-Ends

Shares in Oxford Biomedica (OXB.L) fall as much as 12 percent after investors are spooked by a clinical update which reiterates the results of a late-stage trial where the company missed its key goal, but analysts say the move is unjustified.

"This is a classic case of the market reading the headline and not understanding the real implication of the detailed data," says Ian Wainwright, managing director of life sciences specialist sales at Canaccord Adams.

He points to the positive news in the announcement, which in fact shows that the drug may still help a subset of patients.

"I'd say the sub group analysis in the trial is actually quite positive," adds Paul Cuddon, analyst at KBC Peel Hunt, reiterating his "buy" stance.

This is actually a much better result than expected and proves Trovax has some application which could be used commercially by licensing into other therapies. The initial reaction by very few was to sell but now seeing the opportunistic buying once the news has been digested. Of course the real potentially explosive news is awaited re its development of its product for Parkinsons and Prosavin could be a Blockbuster